PeptideInjectableImmunomodulatorBioregulator peptide

Vilon

Also known as Lys-Glu dipeptide · KE peptide

Written by enwyReviewed 5 Aug 20261 sources0 comments

Vilon (Lys-Glu) is a synthetic dipeptide bioregulator from the Khavinson series, marketed for immune modulation and anti-aging. Evidence is confined to preclinical and small Russian clinical reports from the originating group, with no independent replication.

01 Overview

Vilon is one of the shortest Khavinson bioregulators, a Lys-Glu dipeptide claimed to influence immune function, gene expression and lifespan in animal models. Developer studies report immunomodulatory and geroprotective effects in aged rodents.\n\nNo independent, controlled human trials substantiate these claims. It is sold as a research peptide for injection or nasal use.

02 Mechanism

Proposed to bind DNA and modulate transcription in immune and other tissues, restoring age-impaired function; human mechanism unverified.

03 Dosing

Tier	Dose	Route	Notes
Anecdotal	5–10 mcg/day	IM	Microgram-range Russian protocols; no clinical basis for other populations.

04 Effects

Effect	Magnitude	Evidence
ImmunomodulationRestored age-impaired immune parameters in rodent models.	n/a	Preclinical
Geroprotective claimsReported lifespan effects in animals from the developer group; unconfirmed in humans.	n/a	Preclinical

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Injection-site reactionLocal irritation at injection sites.	Mild	Common	Anecdotal
Unknown human safetyNo independent human safety data.	Moderate	Unquantified	Unconfirmed

06 Legal status

United States

Research chemical; not FDA-approved

Research use only. · as of Jan 2026

07 References

Peptide regulation of immunity and lifespan (Khavinson bioregulators)Biogerontology / Bull Exp Biol Med

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.